Sonoma Pharmaceuticals Wins $300,000 G-Rex Grant to Enhance Treg Therapy Manufacturing

Sonoma Biotherapeutics Secures G-Rex Grant to Advance Treg Therapy Manufacturing

On November 3, 2025, Sonoma Biotherapeutics receives a significant boost in its mission to develop innovative therapies for autoimmune disorders with the announcement of a $300,000 G-Rex® Grant. This grant, awarded by ScaleReady in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, aims to enhance the manufacturing processes for gene-modified regulatory T cell (Treg) therapies. As the field of cell and gene therapy continues to evolve, this funding plays a crucial role in transitioning SonomaBiotherapeutics from traditional open flask technology to a more modern and commercially viable G-Rex platform.

The G-Rex technology is poised to significantly improve the scalability and efficiency of Treg therapy production. John Wilson, CEO of Wilson Wolf and co-inventor of the G-Rex platform, emphasizes that the grant will enable SonomaBiotherapeutics to implement innovative optimization strategies that are essential for successful commercialization. By utilizing closed system G-Rex devices and ProPak™ GMP Cytokines, SonomaBiotherapeutics can achieve a modular manufacturing approach, which is critical for meeting the demands of clinical trials and regulatory standards. This advancement not only enhances the production capabilities but also integrates cutting-edge tools like process analytic technology, further positioning the company at the forefront of Treg therapy development.

Moreover, the G-Rex Grant Program, which has now surpassed $40 million in product commitments, is dedicated to supporting the broader landscape of cell and gene-modified cell therapy (CGT) development. Recipients of this grant gain exclusive access to resources from ScaleReady’s extensive network of partners, which encompasses crucial areas like cGMP manufacturing and regulatory affairs. This collaboration underscores the importance of strategic partnerships in advancing scientific innovations and highlights SonomaBiotherapeutics' commitment to improving treatment options for patients with autoimmune disorders.

In addition to the G-Rex grant, ScaleReady introduces a new initiative called LEAN Cell & Gene™, developed in collaboration with Hanson Wade. This program aims to assist CGT entities in enhancing efficiency and quality within their manufacturing processes through a series of complimentary events. The dual focus on funding and educational resources illustrates a comprehensive approach to fostering growth in the cell and gene therapy sector, ultimately benefiting both the industry and patients in need of novel therapeutic solutions. For further insights into the G-Rex Grant Program or the LEAN Cell & Gene™ series, interested parties are encouraged to contact ScaleReady directly.